Tag: Afamitresgene autoleucel

Quick Take: Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN)

Adaptimmune’s Afami-cel is the first FDA-approved T-cell receptor therapy for synovial sarcoma

byAmy Boyleand1 others

September 30, 2024

Afami-cel (Tecelra) is the first genetically engineered T-cell receptor therapy for synovial sarcoma Afami-cel demonstrated an overall response rate of ...

Survivors of adult-onset cancers associated with increased incidence of cardiovascular disease

Afamitresgene autoleucel as an effective T-cell therapy for synovial sarcoma and liposarcoma

byNeel Mistryand1 others

May 1, 2024

1. Overall response rate to afami-cel in both groups was 37%. 2. The majority of adverse-events were moderate in nature ...

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

No Result

View All Result

Tag: Afamitresgene autoleucel

Adaptimmune’s Afami-cel is the first FDA-approved T-cell receptor therapy for synovial sarcoma

Afamitresgene autoleucel as an effective T-cell therapy for synovial sarcoma and liposarcoma

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2MM+ Premium Access

Recent Reports